As part of its endless push toward true patient-centricity, pharma has talked up its patient support offerings. But is the industry delivering what patients truly want, or what its wealth of behavioral data suggests might be best received?
Congress puts big price tag on innovation in pharma
It has become expensive to develop drugs — especially for specific mutations and small patient populations. But instead of helping pharma adapt, Congress is making innovation more costly.
KOLs are joined by a new breed of channel masters: Physicians who are savvy on social media and whom other clinicians enjoy reading for concise takes on trends, research, or new products.
